Medicaid AMP Final Rule Expected This Month, Draft 340B Rule In July
This article was originally published in The Pink Sheet Daily
Executive Summary
Two rules eagerly awaited by the biopharma industry are targeted for release in the next two months, according to the latest regulatory agenda for HHS: the final rule on calculating the Medicaid average manufacturer price for drugs in June and the proposed rule on 340B program regulations in July.
You may also be interested in...
Medicaid AMP: Manufacturers Have Reason To Hope For Significant Changes In Final Rule
A major regulation that could reshape how the pharmaceutical industry reports drug pricing to the government and pays rebates on Medicaid drugs is slated to be released in final form in 2014. Some Medicaid regulatory experts suggest that CMS could make changes in the final rule that will make it less disruptive to manufacturers’ businesses than they have feared.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.